{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:43:13Z","timestamp":1792798993468,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.mayocp.2015.11.007","type":"journal-article","created":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T10:15:30Z","timestamp":1451902530000},"page":"101-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":418,"title":["Multiple Myeloma: Diagnosis and Treatment"],"prefix":"10.1016","volume":"91","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mayocp.2015.11.007_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2015.11.007_bib2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ajh.23810","article-title":"Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Rajkumar","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib3","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib4","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.007_bib5","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.007_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.007_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A\u00a0long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.mayocp.2015.11.007_bib8","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9727","key":"10.1016\/j.mayocp.2015.11.007_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study [published correction appears in Lancet. 2010;376(9738):332]","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.mayocp.2015.11.007_bib10","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.mayocp.2015.11.007_bib11","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.007_bib12","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.007_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.mayocp.2015.11.007_bib14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2015.11.007_bib15","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342(5):364]","volume":"341","author":"Singhal","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.mayocp.2015.11.007_bib16","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A\u00a0phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.007_bib17","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.007_bib18","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.007_bib19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.mayocp.2015.11.007_bib20","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.007_bib21","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.4065\/81.12.1575","article-title":"Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays","volume":"81","author":"Katzmann","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.007_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/ejh.12478","article-title":"Clinical course and prognosis of non-secretory multiple myeloma","volume":"95","author":"Chawla","year":"2015","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.007_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.007_bib25","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.007_bib26","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.11.007_bib27","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"40","key":"10.1016\/j.mayocp.2015.11.007_bib29","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.mayocp.2015.11.007_bib30","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.007_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(03)01195-1","article-title":"New insights into the pathophysiology of multiple myeloma","volume":"4","author":"Seidl","year":"2003","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.007_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1470-2045(11)70143-7","article-title":"Multiple myeloma and the road to personalised medicine","volume":"12","author":"Russell","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A\u00a0clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.mayocp.2015.11.007_bib34","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.007_bib35","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2009.61","article-title":"Is the international staging system superior to the Durie-Salmon staging system? a comparison in multiple myeloma patients undergoing autologous transplant","volume":"23","author":"Hari","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.007_bib36","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"26","key":"10.1016\/j.mayocp.2015.11.007_bib37","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2015.11.007_bib38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"10.1016\/j.mayocp.2015.11.007_bib39","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma [published correction appears in N Engl J Med. 2005;352(11):1163]","volume":"351","author":"Kyle","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.mayocp.2015.11.007_bib41","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.007_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial [published correction appears in Lancet Oncol. 2010;11(1):14]","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib43","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"issue":"9594","key":"10.1016\/j.mayocp.2015.11.007_bib44","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.mayocp.2015.11.007_bib45","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.007_bib46","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2015.11.007_bib47","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.mayocp.2015.11.007_bib48","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9758","key":"10.1016\/j.mayocp.2015.11.007_bib49","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.007_bib50","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.mayocp.2015.11.007_bib51","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.007_bib52","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.007_bib53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of Total Therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.007_bib54","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2010-01-264333","article-title":"Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy","volume":"116","author":"van Rhee","year":"2010","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.mayocp.2015.11.007_bib55","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A\u00a0phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.007_bib56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2015.11.007_bib57","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ctrv.2014.02.005","article-title":"Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview","volume":"40","author":"Jakubowiak","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.007_bib58","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2015.11.007_bib59","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V122.21.690.690","article-title":"Phase I\/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed\/refractory multiple myeloma [abstract]","volume":"122","author":"Shah","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.11.007_bib60","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood.V122.21.2.2","article-title":"Initial phase 3 results of the First (Frontline Investigation Of Lenalidomide\u00a0+ Dexamethasone Versus Standard Thalidomide) Trial (MM-020\/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT)","volume":"122","author":"Facon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.11.007_bib61","doi-asserted-by":"crossref","unstructured":"Durie B, Hoering A, Rajkumar SV, et\u00a0al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777 [ASH Annual Meeting Abstracts 2015, abstract 25]. American Society of Hematology website. https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper79014.html. Accessed November 10,\u00a02015.","DOI":"10.1182\/blood.V126.23.25.25"},{"key":"10.1016\/j.mayocp.2015.11.007_bib62","doi-asserted-by":"crossref","unstructured":"Moreau P, Hulin C, Macro M, et\u00a0al. Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma: results of the prospective IFM 2013-04 trial [ASH Annual Meeting Abstracts 2015, abstract 393]. American Society of Hematology website. https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper81103.html. Accessed November 10,\u00a02015.","DOI":"10.1182\/blood.V126.23.393.393"},{"key":"10.1016\/j.mayocp.2015.11.007_bib63","doi-asserted-by":"crossref","unstructured":"Attal M, Lauwers-Cances V, Hulin C, et\u00a0al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 trial) [ASH Annual Meeting Abstracts 2015, abstract 391]. American Society of Hematology website. https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper78452.html. Accessed November 10,\u00a02015.","DOI":"10.1182\/blood.V126.23.391.391"},{"issue":"15, suppl","key":"10.1016\/j.mayocp.2015.11.007_bib64","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1200\/jco.2010.28.15_suppl.8014","article-title":"Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): results of IFM2007-02 study [abstract]","volume":"28","author":"Moreau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.007_bib65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study [published correction appears in Lancet Oncol. 2011;12(6):522]","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.mayocp.2015.11.007_bib66","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2015.11.007_bib67","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.007_bib68","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A\u00a0phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.mayocp.2015.11.007_bib69","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/jco.2015.33.15_suppl.8509","article-title":"Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): results from the phase III study ENDEAVOR [abstract]","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"33","key":"10.1016\/j.mayocp.2015.11.007_bib70","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.mayocp.2015.11.007_bib71","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMc1101834","article-title":"Renal improvement in myeloma with bortezomib plus plasma exchange [letter]","volume":"364","author":"Burnette","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib72","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial [published correction appears in Ann Intern Med. 2007;146(6):471]","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mayocp.2015.11.007_bib73","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.mayocp.2015.11.007_bib74","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2003-01-0073","article-title":"Transplantation for multiple myeloma: who, when, how often?","volume":"102","author":"Blad\u00e9","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.007_bib75","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(03)01077-5","article-title":"Management of multiple myeloma: a systematic review and critical appraisal of published studies","volume":"4","author":"Kumar","year":"2003","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2015.11.007_bib76","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/83.10.1131","article-title":"Autologous stem cell transplantation in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and impact of a multidisciplinary quality initiative","volume":"83","author":"Gertz","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib77","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.007_bib78","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"suppl 1, pt 1","key":"10.1016\/j.mayocp.2015.11.007_bib79","first-page":"685a","article-title":"Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM): preliminary results of a prospective randomized trial (CIAM) protocol [abstract 2729]","volume":"88","author":"Facon","year":"1996","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib80","first-page":"42a","volume":"102","author":"Barlogie","year":"2003","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2015.11.007_bib81","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial [published correction appears in J Clin Oncol. 2012;30(29):3654]","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib82","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.007_bib83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.11.007_bib84","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mayocp.2015.11.007_bib85","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2015.11.007_bib86","first-page":"S59","volume":"4","author":"Fermand","year":"2003","journal-title":"Hematol J"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2015.11.007_bib87","first-page":"S61","article-title":"Single vs. tandem autolgous transplantation in multiple myeloma: the GMMG experience [abstract]","volume":"4","author":"Goldschmidt","year":"2003","journal-title":"Hematol J"},{"issue":"13","key":"10.1016\/j.mayocp.2015.11.007_bib88","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib89","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A\u00a0comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2015.11.007_bib90","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib91","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.mayocp.2015.11.007_bib92","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.mayocp.2015.11.007_bib93","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.007_bib94","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.007_bib95","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrclinonc.2012.100","article-title":"Haematological cancer: lenalidomide maintenance\u2014perils of a premature denouement","volume":"9","author":"Rajkumar","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib96","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.mayocp.2015.11.007_bib97","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma [published correction appears in N Engl J Med. 2012;367(3):285]","volume":"366","author":"Palumbo","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib98","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.bmt.1701559","article-title":"Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma","volume":"23","author":"Gertz","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.007_bib99","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"10.1016\/j.mayocp.2015.11.007_bib100","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [published correction appears in N Engl J Med. 2009;361(5):544]","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2015.11.007_bib101","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.007_bib102","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2008.99","article-title":"VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma","volume":"22","author":"Pineda-Roman","year":"2008","journal-title":"Leukemia"},{"issue":"34","key":"10.1016\/j.mayocp.2015.11.007_bib103","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase\u00a0I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2015.11.007_bib104","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A\u00a0phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.007_bib105","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"10.1016\/j.mayocp.2015.11.007_bib106","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib107","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib108","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib109","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.007_bib110","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.mayocp.2015.11.007_bib111","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S A"},{"issue":"29","key":"10.1016\/j.mayocp.2015.11.007_bib112","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1200\/JCO.2012.46.7068","article-title":"Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma","volume":"31","author":"San-Miguel","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.mayocp.2015.11.007_bib113","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"15, suppl","key":"10.1016\/j.mayocp.2015.11.007_bib114","doi-asserted-by":"crossref","first-page":"LBA8512","DOI":"10.1200\/jco.2015.33.18_suppl.lba8512","article-title":"Phase II study of daratumumab (DARA) monotherapy in patients with \u2265 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius) [abstract]","volume":"33","author":"Lonial","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.007_bib115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2015.11.007_bib116","doi-asserted-by":"crossref","unstructured":"Moreau P, Masszi T, Grzasko N, et\u00a0al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and\/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM1 Study (NCT01564537) [ASH Annual Meeting Abstracts 2015, abstract 727]. American Society of\u00a0Hematology website. https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper79829.html. Accessed November 11,\u00a02015.","DOI":"10.1182\/blood.V126.23.727.727"},{"issue":"17","key":"10.1016\/j.mayocp.2015.11.007_bib117","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/archinte.1994.00420170079008","article-title":"Treatment of cancer-associated hypercalcemia: double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone","volume":"154","author":"Gucalp","year":"1994","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.007_bib118","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.007_bib119","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.007_bib120","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases [published correction appears in Cancer. 2001;91(10):1956]","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.007_bib121","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastatses in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"issue":"17","key":"10.1016\/j.mayocp.2015.11.007_bib122","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"9757","key":"10.1016\/j.mayocp.2015.11.007_bib123","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"1 suppl","key":"10.1016\/j.mayocp.2015.11.007_bib124","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3171\/spi.2003.98.1.0021","article-title":"Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients","volume":"98","author":"Fourney","year":"2003","journal-title":"J\u00a0Neurosurg"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.007_bib125","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.mayocp.2015.11.007_bib126","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.007_bib127","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/088506669501000304","article-title":"Hyperviscosity syndrome","volume":"10","author":"Gertz","year":"1995","journal-title":"J\u00a0Intensive Care Med"},{"issue":"20","key":"10.1016\/j.mayocp.2015.11.007_bib128","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.007_bib129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.007_bib130","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/bjc.1996.212","article-title":"A\u00a0prognostic index for multiple myeloma","volume":"73","author":"Grignani","year":"1996","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.007_bib131","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N\u00a0Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615008952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615008952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T19:02:27Z","timestamp":1654023747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619615008952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":131,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0025619615008952"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.11.007","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Myeloma: Diagnosis and Treatment","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}